Article

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-Making

2026-02-05

Abstract excerpt

Core-binding factor acute myeloid leukemia (CBF-AML), defined by the chromosomal rearrangements t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16), has traditionally been classified as a favorable-risk subtype of AML. Nevertheless, relapse occurs in approximately 30–40% of patients, highlighting substantial biological and clinical heterogeneity within this entity. In this review, we synthesize emerging evidence delinea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c0a69b4a-9523-5489-ae4c-8fcdbca2cb56
DOI: 10.20944/preprints202602.0190.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingDOI 10.20944/preprints202602.0190.v1Read

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read

Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.Semantic proximity Read

Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.Semantic proximity Read

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.Semantic proximity Read

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Semantic proximity Read

Clinical characteristics and therapeutic determinants of RUNX1::RUNX1T1 differ from those of CBFB::MYH11 acute myeloid leukemiaSemantic proximity Read

Core-Binding Factor Acute Myeloid LeukemiaSemantic proximity Read

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Semantic proximity Read

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read

The genomic landscape of core-binding factor acute myeloid leukemias.Semantic proximity Read